Recruiting Type 2 Diabetes Studies in Oak Lawn
About Type 2 Diabetes Clinical Trials in Oak Lawn
Type 2 diabetes is a chronic metabolic condition affecting over 37 million Americans, characterized by insulin resistance and progressive loss of beta-cell function. While metformin remains the first-line treatment, the treatment landscape has expanded dramatically with GLP-1 receptor agonists (semaglutide, tirzepatide), SGLT2 inhibitors (empagliflozin, dapagliflozin), and dual GIP/GLP-1 agonists showing both glycemic and cardiovascular benefits. Clinical trials are now exploring triple-hormone agonists, oral GLP-1 formulations, islet cell regeneration therapies, and precision medicine approaches that tailor treatment to individual metabolic profiles. Patients with uncontrolled HbA1c on current medications, those with diabetic complications, or newly diagnosed patients may qualify for enrollment.
There are currently 1 type 2 diabetes clinical trials recruiting participants in Oak Lawn, ILLINOIS. These studies are seeking a combined 240 participants. Research is being sponsored by Hoffmann-La Roche. Clinical trial participation is free and participants receive study-related medical care at no cost.
Type 2 Diabetes Clinical Trials in Oak Lawn — FAQ
Are there type 2 diabetes clinical trials in Oak Lawn?
Yes, there are 1 type 2 diabetes clinical trials currently recruiting in Oak Lawn, ILLINOIS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Oak Lawn?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Oak Lawn research site will contact you about next steps.
Are clinical trials in Oak Lawn free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Oak Lawn studies also compensate for your time and travel.
What type 2 diabetes treatments are being tested?
The 1 active trials in Oak Lawn are testing new therapies including novel drugs, biologics, and treatment approaches for type 2 diabetes.
Data updated March 2, 2026 from ClinicalTrials.gov